KROS | tickerfilter.com

Fundamental analysis

44%

Profitability 43%

Dept financing 19%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.48%

1 Month

-32.04%

3 Months

-46.61%

6 Months

-26.52%

1 Year

0.61%

2 Year

-82.54%

Key data

Stock price

$11.27

P/E Ratio

N/A

DAY RANGE

$11.07 - $11.53

EPS

$1.97

52 WEEK RANGE

$9.12 - $22.55

52 WEEK CHANGE

-$1.53

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

19.718 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-07-2025

BETA

0.91

PUBLIC FLOAT

AVERAGE 10 VOLUME

$553,923

AVERAGE 30 VOLUME

$391,699

Company detail

CEO: Jasbir S. Seehra
Region: US
Website: kerostx.com
Employees: 100
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Keros Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia.

KROS - Keros Therapeutics Inc